# A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis

> **NCT07667322** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 75 (estimated)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Ocrelizumab Co-formulated With rHuPH20

## Key facts

- **NCT ID:** NCT07667322
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-12-17
- **Primary completion:** 2028-02-15
- **Final completion:** 2028-08-01
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2026-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07667322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07667322, "A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07667322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*